Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that two abstracts have been accepted for presentation at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, October 31 through November 4, 2018.
New data will be presented from the following two abstracts:
- “EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects (HS)”
- “EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro”
EDP-938, Enanta’s lead non-fusion inhibitor, is being developed for the treatment of RSV infection. Enanta believes a non-fusion approach differentiates its compounds from fusion inhibitors currently in development for RSV because non-fusion inhibitors target the virus replication machinery and have demonstrated high barriers to resistance against the virus in vitro. EDP-938 has also been shown to reduce viral load below the level of detection in vivo. Additionally, non-fusion inhibitors have the potential of being effective at later stages of infection.
Respiratory syncytial virus (RSV) is a virus that infects the lungs and represents a serious unmet medical need in infants and children, as well as immune-compromised individuals and the elderly. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. Each year, 57,000 to 125,000 children in this group are hospitalized due to RSV infection. Children with compromised (weakened) immune systems due to a medical condition or medical treatment, adults with compromised immune systems and those 65 and older are also at increased risk of severe disease. There is currently no effective treatment available for treating RSV infection.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta’s collaboration with AbbVie, have now been approved around the world as part of AbbVie’s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).
Royalties from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.